Inventiva is burning cash at approximately 3,000% of revenue — an extreme rate — and its market capitalization of roughly $890 million falls below the $1 billion minimum threshold that defines the investable universe for this strategy, removing it from consideration. RSI at 18 and a falling-knife technical setup compound the risk, though the long-term moving average slope remains positive, suggesting the selloff may not yet have found a durable floor.
Thesis pillars
- Extreme Cash Burn Vs Revenue→Stable
- Below Minimum Market Cap Floor↑Improving
- Capitulation Level Rsi Ambiguous Trend↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026
Inventiva S.A. - American Depos (IVA) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $3.71: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Below long-term trend.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a... Read more
Sell if holding. Engine safety override at $3.71: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 61. Score 4.7/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 154d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Inventiva S.A. - American Depos
Latest news
- NEWS Guggenheim Sticks to Its Buy Rating for Inventiva (IVA) - The Globe and Mail — The Globe and Mail positive
- NEWS Analysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Envista Holdings (NVST) and Inventiva (IVA) - — The Globe and Mail positive
- NEWS WTA roundup: Defending champ Iva Jovic returns to Guadalajara final - Reuters — Reuters neutral
- NEWS Inventiva S.A. (IVA): Analyst Ratings Signal A 297% Upside Potential For Biotech Innovator - DirectorsTalk Interviews — DirectorsTalk Interviews positive
- NEWS Piper Sandler Maintains Buy Rating and $26 Price Target for Inventiva — fiscal.ai Oct 24, 2026 positive
Generated 2026-10-29T11:14:33Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.71: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 61. Prior stop was $3.45. Score 4.7/10, moderate confidence.
Resistance target: $3.79 (+2.2% upside). Prior stop was $3.45. Stop-loss: $3.45.
DATA_ISSUE: analyst_target_implausible (raw $15.20 vs price $3.71 — ratio 4.1×). Rejected, falling back to technical TP.; Quality below floor (3.7 < 4.0).
Inventiva S.A. - American Depos trades at a P/E of N/A (forward -5.0). TrendMatrix value score: 5.0/10. Verdict: Sell.
15 analysts cover IVA with a consensus score of 4.4/5. Average price target: $15.
What does Inventiva S.A. - American Depos do?Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies...
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.